The working group noted several impediments to progress, including a lack of awareness around the potential role of the private sector, a lack of supporting regulation and legislative capacity, confl icting public and private objectives, constrained government capability to engage with the wide range of private sector entities, and inadequate use of data to support action, target setting, and monitoring processes.
The group noted that confl icts of interest are not ubiquitous and many commercial entities have objectives that closely align with NCD prevention and control. The private sector is heterogeneous, and many businesses infl uence NCDs positively, including those involved with pharmaceuticals, food, sports and fi tness, insurance, banking, advertising, entertainment, transport, and infrastructure. Engagement with businesses can mitigate harm and leverage expertise and resources to bolster the global NCD response.
This pro-engagement perspective resonates with calls in the Addis Abba Action Agenda to "unlock the transformative power of the private sector"; 6 however, counterpoised paragraphs acknowledge the need for strengthened regulatory frameworks to align business incentives with public goals. Balancing potential gains to public health with potential confl icts of interest is an ongoing challenge, and the working group has developed a series of principles to facilitate eff ective public-private engagement.
First, there must be clear policy goals for the issue at hand, whether these are expanding access to medications, improving public transport, regulating harmful substances, or upgrading water and sanitation infrastructure. Clear goals require careful problem defi nition, articulation of the desired outcome, and a system-wide approach for evaluating potential solutions.
Second, all of the stakeholders that might have a role to play in a potential partnership to prevent and manage NCDs should be identifi ed, including academics, government departments, civil society, philanthropic organisations, and the full gamut of private sector entities. Full assessments of the potential costs, benefi ts, risks, and impacts are required before public health agencies enter into specifi c partnerships.
Due diligence is essential and should pay special attention to the scope and purpose of the mooted relationship, the partner's interests, policies, values, and past performance. It is important to actively manage real, perceived, and potential confl icts of interest, and to maintain transparent interactions at all times. Such transparency might include making correspondences and meeting minutes publicly available. The need to identify and manage confl icts of interest should be communicated throughout all relevant institutions, with high-level organisational oversight. There should be clear rules on disclosing and managing confl icts for individual offi cials, especially around gifts, providing services, and managing research funding. Failure to manage perceived confl icts of interest can cause reputational damage, undermine public health work in other areas, and whitewash the image of unscrupulous companies.
The parties involved in any partnership should consider whether formal arrangements such as legal contracts or memoranda of understanding are required for the proposed work. Ongoing monitoring and evaluation is important to ensure that both parties play by the rules.
Public-private enterprises are more likely to succeed where governments have established statutory and regulatory frameworks that support partnerships and protect the public. Governments can also help to align private sector incentives with national objectives through the use of taxes, subsidies, and reduced compliance costs.
Several of these recommendations are mirrored in the recently adopted WHO Framework for Engagement with Non-State Actors. 7 Although this framework deals exclusively with WHO partnerships, the themes of due diligence, risk assessment, transparency, and accountability all feature prominently. Both sets of recommendations are based on the assumption that some degree of engagement with many private sector actors is essential for progress in contemporary global health.
Critics of private sector engagement argue that any such collaboration exposes population health to undue commercial infl uence and can lead to the socalled corporate capture of public health institutions. 8 Although there are acknowledged risks, it is important to recognise the diversity among private-sector actors and the absolute centrality of commercial determinants of health in the 21st century.
1 Although the public health community can feel justifi ably uneasy about working with private sector actors directly causing disease and disability, the general consensus is that some degree of engagement is essential (with the exception of arms and tobacco). 9 The working group's fi ndings chart a course though this diffi cult territory.
The principles outlined here and detailed in the full report 5 represent one step in an iterative process that will be strengthened by ongoing discussion. Discriminating between confl icts and confl uences of interest is complex and guidance will need to evolve over time. The Global Coordination Mechanism is an organisational partnership that already brings public, private, and third sector agents together in pursuit of NCD prevention and control. In its role as a broker and convener we welcome ongoing dialogue and engagement on this issue.
